[go: up one dir, main page]

AR076861A1 - Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2 - Google Patents

Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2

Info

Publication number
AR076861A1
AR076861A1 ARP100101613A ARP100101613A AR076861A1 AR 076861 A1 AR076861 A1 AR 076861A1 AR P100101613 A ARP100101613 A AR P100101613A AR P100101613 A ARP100101613 A AR P100101613A AR 076861 A1 AR076861 A1 AR 076861A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
substituted
substituents
3alkyl
Prior art date
Application number
ARP100101613A
Other languages
English (en)
Original Assignee
Addex Pharma Sa
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharma Sa, Ortho Mcneil Janssen Pharm filed Critical Addex Pharma Sa
Publication of AR076861A1 publication Critical patent/AR076861A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de triazolo[4,3-a]piridina de formula (1). Los compuestos son moduladores alostéricos positivos del receptor de glutamato metabotropico subtipo 2 (ômGluR2ö), utiles para el tratamiento o la prevencion de trastornos neurologicos y psiquiátricos asociados con una disfuncion del glutamato y enfermedades en las cuales está involucrado el subtipo mGluR2 de receptores metabotropicos, también se refiere a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos para la prevencion o el tratamiento de trastornos neurologicos y psiquiátricos y enfermedades en las cuales está involucrado mGluR2. Reivindicacion 1: Un compuesto de formula (1) o una forma estereoquímicamente isomérica de dicho compuesto en donde n se selecciona del grupo que consiste en 0, 1 y 2; m se selecciona del grupo que consiste en 0, 1, y 2; R se selecciona de metilo o trifluorometilo; R1 se selecciona del grupo que consiste en hidrogeno; alquilo C1-6, (alquiloxi C1-3)- alquilo C1-3, [(alquiloxi C1-3)alquiloxi C1-3]alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; fenilo no sustituido; bencilo no sustituido; bencilo sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3 , alquiloxi C1-3, alquiloxi C1-3alquiIo C1-3, hidroxialquilo C1-3, ciano, hidroxilo, amino, C(=O)R', C(=O)O', C(=O)NR'Rö, mono- o di(alquil C1-3)amino, morfolinilo, (cicloalquil C3-7)alquiloxi C1-3, trifluorometilo y trifluorometoxi, en donde R' y Rö se seleccionan independientemente de hidrogeno y alquilo C1-6, (benciloxi)alquilo C1-3, cicloalquilo C3-7 no sustituido; cicloalquilo C3-7 sustituido con alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; (cicloalquil C3-7)alquilo C1-3; [(cicloalquil C3-7)alquiloxi C1-3]alquilo C1-3; (cicloalquil C3-7)alquiloxi C1-3; 4-(2,3,4,5-tetrahidro- benzo[f][1,4]oxazepin)metilo; Het1, Het1alquilo C1-3, Het2 y Het2alquilo C1-3; R2 se selecciona del grupo que consiste en ciano; halo; alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; alquilo C1-3, cicloalquilo C3-7 y (cicloalquil C3-7)alquilo C1-3; el anillo L es un heterociclo que contiene N seleccionado del grupo que consiste en (L-a), (L-b), (L-c), (L-d), (L-e), (L-f), (L-g) y (L-h) en donde R3a se selecciona del grupo que consiste en alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; cicloalquilo C3-7 no sustituido; cicloalquilo C3-7 sustituido con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente o hidroxilo; fenilo no sustituido; fenilo sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, hidroxialquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, ciano, hidroxilo, amino, carboxilo, alquiloxi C1-3-alquilo C1-3, alquiloxi C1-3, alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquil C1-3carbonilo, mono- y di(alquil C1-3)amino y morfolinilo; (fenil)alquilo C1-3 no sustituido; (fenil)alquilo C1-3 en donde el fenilo y la parte alquilo C1-3 del sustituyente pueden estar cada uno independientemente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, hidroxialquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, ciano, hidroxilo, amino, carboxilo, alquiloxi C1-3alquilo C1-3, alquiloxi C1-3, alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquilo C1-3carbonilo, mono- o di(alquil C1-3)amino, morfolinilo y (cicloalquil C3-7)alquiloxi C1-3, feniloxi no sustituido; feniloxi sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquiloxi C1-3, y alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; feniloxi no sustituido(alquilo C1-3)oxi; (fenilalquilo C1-3)oxi no sustituido; fenil(alquilo C1-3)oxi en donde la parte fenilo del sustituyente está sustituida con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquiloxi C1-3, y alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; feniloxialquilo C1-3 no sustituido; (feniloxi)alquilo C1-3 sustituido con 1 o 2 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquiloxi C1-3, y alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; fenilamino no sustituido; fenilamino sustituido con 1 o 2 sustituyentes halo independientemente seleccionados; (fenilalquil C1-3)amino; (fenilamino)(alquilo C1-3); (cicloalquil C3-7)alquilo C1-3, [fenil(cicloalquil C3-7)]alquilo C1-3; Het1; Het2; Het2oxi; Het2metiloxi; Het3 y fenilo con dos sustituyentes vecinos que, tomados juntos, forman un radical bivalente de formula -N=CH-NH- (a), -CH=CH-NH- (b), o -O-CH2-CH2-NH- (c); R4a se selecciona del grupo que consiste en hidrogeno; halogeno; trifluorometilo; trifluorometoxi; hidroxilo; alquilo C1-3, alquiloxi C1-3, hidroxialquilo C1-3, hidroxil-alquiloxi C1-3, fluoroalquilo C1-3, fluoroalquiloxi C1-3, ciano; fenilo no sustituido; y fenilo sustituido con 1 o 2 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquiloxi C1-3, hidroxialquilo C1-3, trifluorometilo y trifluorometoxi; o CR3aR4a forma un radical de formula (d), (e), (f), (g) o (h); en donde cada W1d, W1e, W2e y W1f se selecciona independientemente de CH y N; cada R7d, R7e, R7f, R7g, R8d, R8e, R8f, R8g se selecciona independientemente de hidrogeno, metilo y fluoro; o cada CR7dR8d, CR7eR8e, CR7fR8f, CR7gR8g forma un grupo carbonilo; cada R9d, R9e, R9f y R9g es fluoro; cada q1, q2, q3 o q4 se selecciona independientemente de 0, 1 y 2; r es 0 o 1; s es 0 o 1; cada R3b y R3c se selecciona del grupo que consiste en alquilo C1-3 alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; fenilo no sustituido; fenilo sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, hidroxialquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, ciano, hidroxilo, amino, carboxilo, alquiloxi C1-3aIquilo C1-3, alquiloxi C1-3, alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquil C1- 3carbonilo, mono- y di(alquil C1-3)amino, y morfolinilo; (fenil)alquilo C1-3 no sustituido; (fenil)-alquilo C1-3 en donde el fenilo y la parte alquilo C1-3 del sustituyente pueden estar cada uno independientemente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, hidroxialquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, ciano, hidroxilo, amino, carboxilo, alquiloxi C1-3alquilo C1-3, alquiloxi C1-3, alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquil C1-3carbonilo, mono- o di(alquil C1-3)amino, morfolinilo, cicloalquilo C3-7, (cicloalquil C3-7)alquilo C1-3, y (cicloalquil C3-7)-alquiloxi C1-3, (feniloxi)alquilo C1-3 no sustituido; (feniloxi)-alquilo C1-3 sustituido con 1 o 2 sustituyentes seleccionados independientemente del grupo que consiste en halo, alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, alquiloxi C1-3, y alquiloxi C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente; (fenilamino)(alquilo C1-3); fenilo con dos sustituyentes vecinos que, tomados juntos, forman un radical bivalente de formula (a), (b) o (c) como se definio anteriormente; Het1, Het2, Het3, cicloalquilo C3-7 no sustituido; cicloalquilo C3-7 sustituido con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-3, alquilo C1-3 sustituido con uno o varios sustituyentes halo seleccionados independientemente, o hidroxilo; (cicloalquil C3-7)alquilo C1-3 y [fenil-(cicloalquil C3-7)]alquilo C1-3; R3d y R4d se seleccionan cada uno independientemente del grupo que consiste en hidrogeno y alquilo C1-3; cada R5a, R5b, R5c, R5d, R6a, R6b, R6c y R6d se selecciona independientemente del grupo que consiste en hidrogeno y alquilo C1-3; o cada par R5aR6a, R5bR6b, R5cR6c, R5dR6d son sustituyentes en el mismo átomo de carbono y cada CR5aR6a, CR5bR6b, CR5cR6c, CR5dR6d juntos forman un (C=O) o un radical cicloalquilideno C3-7; cada R10a, R10b y R10c se selecciona de H, alquilo C1-3 y alquiloxi C1-3; en donde, en (L-e), cuando t es 1 o 2, R11 es hidrogeno y R12 se selecciona de un sustituyente seleccionado del grupo que consiste en fenilo, feniloxi y fenilamino, cada uno de los cuales puede estar opcionalmente sustituido con 1 o 2 sustituyentes halo; o cuando t es 1 o 3, entonces CR11R12 forman un radical de formula (i) o formula (j) en donde cada R13i y R13j se selecciona independientemente de metilo y trifluorometilo; cada R14i o R14j es fluoro; cada u1 y u2 es independientemente 0, 1 o 2; v1 se selecciona del grupo de 0, 1 y 2; v2 se sele
ARP100101613A 2009-05-12 2010-05-11 Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2 AR076861A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09160059 2009-05-12

Publications (1)

Publication Number Publication Date
AR076861A1 true AR076861A1 (es) 2011-07-13

Family

ID=41429238

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101613A AR076861A1 (es) 2009-05-12 2010-05-11 Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2

Country Status (31)

Country Link
US (4) US8937060B2 (es)
EP (1) EP2430022B1 (es)
JP (1) JP5634506B2 (es)
KR (1) KR101753826B1 (es)
CN (1) CN102439008B (es)
AR (1) AR076861A1 (es)
AU (1) AU2010246609B2 (es)
BR (1) BRPI1012870B8 (es)
CA (1) CA2760741C (es)
CL (1) CL2011002838A1 (es)
CY (1) CY1114718T1 (es)
DK (1) DK2430022T3 (es)
EA (1) EA020672B1 (es)
ES (1) ES2440001T3 (es)
HR (1) HRP20131122T1 (es)
IL (1) IL215912A (es)
JO (1) JO2907B1 (es)
ME (1) ME01573B (es)
MX (1) MX2011011964A (es)
MY (1) MY161325A (es)
NZ (1) NZ596078A (es)
PL (1) PL2430022T3 (es)
PT (1) PT2430022E (es)
RS (1) RS53075B (es)
SG (2) SG10201402250TA (es)
SI (1) SI2430022T1 (es)
SM (1) SMT201400003B (es)
TW (1) TWI468406B (es)
UA (1) UA108070C2 (es)
WO (1) WO2010130424A1 (es)
ZA (1) ZA201107834B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
DE602008004794D1 (de) * 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
KR101564806B1 (ko) 2010-05-13 2015-10-30 암젠 인크 Ｐｄｅ10 저해제로서 유용한 질소 헤테로시클릭 화합물
AU2011328196A1 (en) * 2010-11-08 2013-05-02 Janssen Pharmaceuticals, Inc. Radiolabelled mGluR2 PET ligands
CA2814998C (en) * 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) * 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US8993591B2 (en) * 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US8765767B2 (en) 2012-03-16 2014-07-01 Bristol-Myers Squibb Company Positive allosteric modulators of mGluR2
WO2013192306A1 (en) * 2012-06-21 2013-12-27 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) * 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) * 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
US10017514B2 (en) 2014-08-01 2018-07-10 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JO3601B1 (ar) 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
US10220032B2 (en) 2014-08-01 2019-03-05 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6689856B2 (ja) 2014-12-03 2020-04-28 ヤンセン ファーマシューティカ エヌ．ベー． ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
AU2015359352B2 (en) * 2014-12-11 2020-07-02 Janssen Pharmaceutica Nv 1,2,4-triazolo(4,3-a)pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors
PT3389727T (pt) 2015-12-18 2020-10-30 Janssen Pharmaceutica Nv Ligantes pet de mglur2/3 radiomarcados
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
CA3037537C (en) * 2016-09-27 2021-06-15 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
EP3548033B1 (en) 2016-11-28 2024-04-10 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
AU2019278814B2 (en) 2018-05-30 2025-12-18 Praxis Precision Medicines, Inc. Ion channel modulators
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020231849A1 (en) * 2019-05-10 2020-11-19 The Broad Institute, Inc. Methods for treating disorders associated with sleep spindle deficits
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2021155196A1 (en) * 2020-01-31 2021-08-05 The General Hospital Corporation Modulators of metabotropic glutamate receptor 2
US20240208983A1 (en) * 2021-04-02 2024-06-27 Vanderbilt University 1,2,4-triazolo[4,3-a]pyridine derivatives as negative allosteric modulators of metabotropic glutamate receptor 2
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
CN116217571B (zh) * 2023-03-28 2024-11-15 上海锐谱医药科技有限公司 一种制备药物砌块1,2,4-三唑并[4,3-a]吡啶-3-胺的方法

Family Cites Families (475)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976146A (en) 1958-11-28 1961-03-21 Eastman Kodak Co Novel cyan-forming couplers
BE790440A (es) 1971-10-23 1973-04-24 Bayer Ag
JPS538707B2 (es) 1974-02-05 1978-03-31
JPS5752334B2 (es) 1974-02-05 1982-11-06
JPS50106981U (es) 1974-02-08 1975-09-02
US3906953A (en) 1974-05-23 1975-09-23 American Optical Corp Endoscopic surgical laser system
SU509578A1 (ru) 1974-09-19 1976-04-05 Стерлитамакский Химический Завод Способ получени пропилендиаминов
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
IE43079B1 (en) 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
FR2311776A1 (fr) 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
JPS5382783U (es) 1976-12-13 1978-07-08
JPS5382783A (en) 1976-12-29 1978-07-21 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivs and process for their preparation
JPS5752334Y2 (es) 1977-03-16 1982-11-13
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4432979A (en) 1981-10-26 1984-02-21 William H. Rorer, Inc. Pyridone compounds
EP0082023A3 (en) 1981-12-16 1983-07-20 Sankyo Company Limited Thienopyrimidine derivatives, their preparation and their medical use
US4358453A (en) 1982-01-08 1982-11-09 Schering Corporation 1,2,4-Triazolo[4,3-a]pyridines
US4520025A (en) 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US4550166A (en) 1984-05-21 1985-10-29 American Cyanamid Company (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines
DE3717561A1 (de) 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
US4866074A (en) 1987-05-08 1989-09-12 Rorer Pharmaceutical Corporation Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5260293A (en) 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
GB8804448D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
DE68923527D1 (de) 1988-10-20 1995-08-24 Sandoz Ag Faserreaktive Azofarbstoffe.
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH02277044A (ja) 1989-04-19 1990-11-13 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5280026A (en) 1989-05-30 1994-01-18 Smithkline Beecham Intercredit B.V. Thienopyrimidines
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
US4978663A (en) 1989-08-16 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 5-(1-aminocyclohexyl)-2(1H)-pyridinone compounds which have pharmaceutical utility
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
DE3940480A1 (de) 1989-12-07 1991-06-13 Bayer Ag Chromogene enaminverbindungen, ihre herstellung und verwendung als farbbildner
AU6979091A (en) 1989-12-22 1991-07-24 Upjohn Company, The Pyridinones useful as antiatherosclerotic agents
FR2657610A1 (fr) 1990-01-29 1991-08-02 Rhone Poulenc Agrochimie Triazolopyridines herbicides.
GB9104238D0 (en) 1990-03-16 1991-04-17 Ici Pharma 3-tetrazolylthiomethyl cephalosporin antibiotics
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
EP0452002A3 (en) 1990-03-30 1992-02-26 Dowelanco Thienopyrimidine derivatives
RU1796625C (ru) 1990-06-27 1993-02-23 Киевский Государственный Университет Им.Т.Г.Шевченко 3-Амино-7-нитро-4(2,3,4-триметоксифенил)-2-фенил-1(2Н)изохинолон, обладающий аналептическим действием
EP0478195B1 (en) 1990-09-21 1999-05-26 Rohm And Haas Company Dihydropyridazinones and pyridazinones as fungicides
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
AU1532492A (en) 1991-04-18 1992-11-17 Dr. Lo Zambeletti S.P.A. Use of heterocyclic compounds for the treatment of inflammatory pain
DE4122240A1 (de) 1991-07-05 1993-01-07 Boehringer Mannheim Gmbh Dibenz(b,e)azepinderivate und diese enthaltende arzneimittel
US5332750A (en) 1991-09-04 1994-07-26 Merck Patent Gesellschaft Mit Beschrankter Haftung 1,2-dihydro-2-oxopyridines
DE4129340A1 (de) 1991-09-04 1993-03-11 Merck Patent Gmbh 1,2-dihydro-2-oxopyridine
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5204198A (en) 1991-10-28 1993-04-20 Eastman Kodak Company Photoelectrographic elements utilizing nonionic sulfonic acid photogenerators
US5416099A (en) 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4221583A1 (de) 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
AU668694B2 (en) 1991-12-19 1996-05-16 Sanofi-Synthelabo Saccharin derivative proteolytic enzyme inhibitors
US5378720A (en) 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
GB9200293D0 (en) 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH05204071A (ja) 1992-01-29 1993-08-13 Konica Corp ハロゲン化銀写真感光材料
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
DE4206045A1 (de) 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
JPH06110557A (ja) 1992-09-28 1994-04-22 Stec Kk マスフローコントローラ
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
AU660132B2 (en) 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
JPH06211798A (ja) 1993-01-19 1994-08-02 Tosoh Corp テトラヒドロイソキノリノン誘導体及びその製造方法
JPH06211797A (ja) 1993-01-19 1994-08-02 Tosoh Corp テトラヒドロイソキノリン誘導体、その製法及び抗真菌剤
SE9300657D0 (sv) 1993-02-26 1993-02-26 Astra Ab New compounds
US5814645A (en) 1993-03-24 1998-09-29 Bayer Aktiengesellschaft Arylor hetaryl substituted nitrogen heterocycles and their use as pesticides
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
JPH07101861A (ja) 1993-08-10 1995-04-18 Tanabe Seiyaku Co Ltd 抗喘息薬
DE4326758A1 (de) 1993-08-10 1995-02-16 Basf Ag [1,3,4]Triazolo[1,5-a]pyridine
SK21596A3 (en) 1993-08-19 1997-03-05 Janssen Pharmaceutica Nv Application of substituted aryloxyalkyl diamines, these substances single, producing method thereof, pharmaceutical compositions on their base and their producing method
PL181385B1 (pl) 1993-08-19 2001-07-31 Janssen Pharmaceutica Nv Nowe pochodne dihydrobenzopiranu o wlasciwosciach naczyniozwezajacych, kompozycja farmaceutyczna i sposób wytwarzania pochodnych dihydrobenzopiranu PL PL PL PL PL PL
AU7467294A (en) 1993-08-20 1995-03-21 Banyu Pharmaceutical Co., Ltd. Tyrosine kinase inhibitor
JP3701984B2 (ja) 1993-08-31 2005-10-05 サントリー株式会社 ラベル化シクロプロパン誘導体およびその製造方法
US5424435A (en) 1993-10-18 1995-06-13 Olin Corporation 1-hydroxy-6-substituted-2-pyridones
US5500420A (en) 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
ATE205479T1 (de) 1994-03-10 2001-09-15 Fujisawa Pharmaceutical Co Naphtalen-derivate als prostaglandin i2 agonisten
ES2079323B1 (es) 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
GB9416554D0 (en) 1994-08-19 1994-10-12 Ciba Geigy Ag Glutamate receptor
WO1996005828A1 (en) 1994-08-24 1996-02-29 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
US5512576A (en) 1994-12-02 1996-04-30 Sterling Winthrop Inc. 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
DE19507522C2 (de) 1995-03-03 2003-05-28 Basf Ag Verfahren zur Herstellung von 3,4-Dihydroisochinolinverbindungen und 3,4-Dihydroisochinolinium-Salzen
TW324008B (en) 1995-03-13 1998-01-01 Ishihara Sangyo Kaisha Pyridone sulfonylurea compound, its production process and weed killer containing such compound
DE19510965A1 (de) 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
EP0826671B1 (en) 1995-04-27 2004-12-29 Mitsubishi Pharma Corporation Heterocyclic amide compounds and medicinal use of the same
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
US5659033A (en) 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
PL184808B1 (pl) 1995-09-15 2002-12-31 Sanofi Synthelabo Pochodne 2(1H)-chinolonu, sposób ich otrzymywania oraz ich zastosowanie terapeutyczne
JPH1045750A (ja) 1995-09-20 1998-02-17 Takeda Chem Ind Ltd アゾール化合物、その製造方法及び用途
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
AU711142B2 (en) 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
EP0880501A1 (en) 1996-02-02 1998-12-02 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
US6084084A (en) 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US5710274A (en) 1996-02-28 1998-01-20 Neurogen Corporation N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5756518A (en) 1996-04-02 1998-05-26 Kowa Co., Ltd. Phenylene derivatives
JPH1029979A (ja) 1996-04-12 1998-02-03 Ajinomoto Co Inc 新規ピリジン誘導体
WO1997046532A1 (en) 1996-06-03 1997-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4h-isoquinolin-1,3-diones and their use as anti-inflammatory agents
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
DE69718177T2 (de) 1996-08-14 2003-10-23 Astrazeneca Ab, Soedertaelje Substituierte pyrimidinderivate und ihre pharmazeutische anwendung
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
DE19638484A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
HU224918B1 (en) 1997-01-24 2006-04-28 Conpharma As Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
FR2759366B1 (fr) 1997-02-11 1999-04-16 Centre Nat Rech Scient Composes constituant notamment des effecteurs de recepteurs du systeme nerveux central sensibles aux amino acides neuroexcitateurs, leur preparation et leurs applications biologiques
US6262068B1 (en) 1997-02-21 2001-07-17 Bristol-Myers Squibb Company Lactam derivatives as antiarrhythmic agents
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
CA2296310A1 (en) 1997-07-18 1999-01-28 Werner Tuckmantel Bicyclic metabotropic glutamate receptor ligands
DE69804273T2 (de) 1997-07-18 2002-10-31 F. Hoffmann-La Roche Ag, Basel 5h-Thiazolo[3,2-a]pyrimidinderivate
AU737008B2 (en) 1997-07-31 2001-08-09 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing TNFalpha levels
PL192029B1 (pl) 1997-08-14 2006-08-31 Hoffmann La Roche Zastosowanie heterocyklicznych eterów winylowych, nowe heterocykliczne etery winylowe, sposób ich wytwarzania i środek farmaceutyczny
US6358975B1 (en) 1997-08-15 2002-03-19 Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9740998A (en) 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
ES2237850T3 (es) 1997-10-14 2005-08-01 Mitsubishi Pharma Corporation Compuestos de piperazina y su uso medicinal.
WO1999021992A2 (en) 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
JP4321737B2 (ja) 1997-12-17 2009-08-26 塩野義製薬株式会社 新規ピリジン化合物
EP1045836B1 (en) 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
US6013672A (en) 1997-12-18 2000-01-11 Uab Research Foundation Agonists of metabotropic glutamate receptors and uses thereof
AU755421B2 (en) 1997-12-19 2002-12-12 Amgen, Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
IT1298155B1 (it) 1998-01-19 1999-12-20 Moreno Paolini Composti pirimidin 3-ossido per il trattamento delle patologie muscolo-scheletriche, in particolare per il trattamento della
US6664250B2 (en) 1998-01-20 2003-12-16 Bristol-Myers Squibb Co. Lactam derivatives as antiarrhythmic agents
DK1052246T3 (da) 1998-01-28 2003-06-16 Taisho Pharmaceutical Co Ltd Fluorholdige aminosyrederivater
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
EP1064256B1 (en) 1998-03-17 2004-08-04 Pfizer Products Inc. Bicyclo [2.2.1] heptanes and related compounds
ID27165A (id) 1998-04-08 2001-03-08 Novaris Ag Herbisida-herbisida n-piridonil
AU3170099A (en) 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
DE19822198C2 (de) 1998-05-16 2003-02-13 Wella Ag Oxonolfarbstoffe enthaltende Mittel und Verfahren zur Erzeugung von semipermanenten Färbungen auf Haaren
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
ATE269293T1 (de) 1998-08-31 2004-07-15 Taisho Pharmaceutical Co Ltd 6-fluoro(3.1.0)hexan-derivate
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
US6284759B1 (en) 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
SE9803518D0 (sv) 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
AU1308400A (en) 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
PE20001236A1 (es) 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
EP1006112A1 (en) 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
WO2000034244A1 (en) 1998-12-04 2000-06-15 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
GB9908175D0 (en) 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
WO2000069816A1 (en) 1999-05-17 2000-11-23 Eli Lilly And Company Metabotropic glutamate receptor antagonists
HK1048635A1 (zh) 1999-06-02 2003-04-11 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1189873A1 (en) 1999-06-03 2002-03-27 Lilly, S.A. Excitatory amino acid receptor modulators
JP4783967B2 (ja) 1999-07-21 2011-09-28 大正製薬株式会社 含フッ素アミノ酸誘導体を有効成分とする医薬
US6350763B1 (en) 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
AU6420700A (en) 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7040838B2 (en) 1999-08-27 2006-05-09 Kristar Enterprises, Inc. High capacity catch basin filtration system with adjustable deflector ring
CN2390948Y (zh) 1999-09-17 2000-08-09 徐平武 混凝土屋顶、楼面施工金属组合专用模具
SI1224175T1 (en) 1999-10-15 2004-08-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
HUP0203142A3 (en) 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
DE60017179T2 (de) 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
GB2355982A (en) 1999-11-03 2001-05-09 Lilly Co Eli Heterocyclic amino acids
AU2220801A (en) 1999-12-22 2001-07-03 Kyorin Pharmaceutical Co. Ltd. Tricyclic compounds and addition salts thereof
HUP0204496A3 (en) 2000-01-20 2004-07-28 Eisai Co Ltd Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
GB0002100D0 (en) 2000-01-28 2000-03-22 Novartis Ag Organic compounds
WO2001056990A2 (en) 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
DE60110391T2 (de) 2000-02-25 2006-01-26 F. Hoffmann-La Roche Ag Adenosin-rezeptor modulatoren
DE10012373A1 (de) 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
AU2001249399A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Isoquinolone inhibitors of factor xa
GB0007193D0 (en) 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CN1209336C (zh) 2000-04-28 2005-07-06 日本农药株式会社 生产2－卤代苯甲酸的方法
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
US20020009713A1 (en) 2000-05-11 2002-01-24 Miller Freda D. Methods for identifying modulators of neuronal growth
WO2001085716A1 (en) 2000-05-11 2001-11-15 Kyowa Hakko Kogyo Co., Ltd 2-piperidone compounds for the treatment of cancer
MXPA02011053A (es) 2000-05-11 2004-08-19 Kenneth Curry Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
US7081481B2 (en) 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
JP3924531B2 (ja) 2000-05-31 2007-06-06 田辺製薬株式会社 αＬβ２介在細胞接着阻害剤
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
JP2002003401A (ja) 2000-06-27 2002-01-09 Japan Science & Technology Corp 脳由来神経栄養因子誘導剤
JP2002012533A (ja) 2000-06-27 2002-01-15 Kao Corp 染毛剤組成物
AU2001276610A1 (en) 2000-06-27 2002-01-08 Centre National De La Recherche Scientifique-Cnrs Mammal 2p domain mechano-sensitive k+ channel, cloning and applications thereof
CA2411059A1 (en) 2000-06-28 2002-12-06 Taisho Pharmaceutical Co., Ltd. Novel dicarboxylic acid derivatives
DE10031390A1 (de) 2000-07-03 2002-01-17 Knoll Ag Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6861530B2 (en) 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
JP2002040252A (ja) 2000-07-27 2002-02-06 Shiseido Co Ltd コレステリック液晶層を含む光学シート、それを用いた情報記録体、情報記録方法並びに情報判別方法
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
DE60140126D1 (de) 2000-08-11 2009-11-19 Eisai R&D Man Co Ltd 2-aminopyridin-verbindungen und ihre verwendung als medikamente
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
AU2002213422A1 (en) 2000-09-13 2002-03-26 Georgetown University Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
JP2002105085A (ja) 2000-09-28 2002-04-10 Yamanouchi Pharmaceut Co Ltd 新規イミダゾチアゾール誘導体
EP1332133B1 (en) 2000-10-02 2008-07-09 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
DE10058663A1 (de) 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
JP2002308882A (ja) 2001-02-08 2002-10-23 Yamanouchi Pharmaceut Co Ltd チエノピリミジン誘導体
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
AU2002308354A1 (en) 2001-03-08 2002-09-24 Ilfa Industrieelektronik Und Leiterplattenfertigung Aller Art Gmbh Multilayer printed circuit board
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2002079498A1 (en) 2001-04-02 2002-10-10 Merck & Co., Inc. In vivo methods of determining activity of receptor-type kinase inhibitors
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
SI1379522T1 (en) 2001-04-12 2005-04-30 F. Hoffmann-La Roche Ag DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
DK1379511T3 (da) 2001-04-12 2005-11-07 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
RU2003135424A (ru) 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
CA2448306A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications
CA2448317A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating glaucoma v
AU2002310156A1 (en) 2001-06-05 2002-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
JPWO2002102807A1 (ja) 2001-06-14 2004-09-30 萬有製薬株式会社 新規イソキサゾロピリドン誘導体及びその用途
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
JP2003012653A (ja) 2001-06-28 2003-01-15 Yamanouchi Pharmaceut Co Ltd キナゾリン誘導体
EP1411941A2 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
DE60228103D1 (de) 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TW200406466A (en) 2001-11-13 2004-05-01 Ciba Sc Holding Ag Compositions comprising at least one oxonol dye and at least one metal complex
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2005518376A (ja) 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 化合物およびホルモン感受性リパーゼの活性を低下させるためのその使用
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
CN1281274C (zh) 2001-12-27 2006-10-25 大正制药株式会社 6－氟双环[3.1.0]己烷衍生物
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2003064428A1 (en) 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
JP2005516988A (ja) 2002-02-07 2005-06-09 ユニバーシティー オブ マイアミ シュヴァン細胞およびホスホジエステラーゼインヒビターに基づく治療
US20040116489A1 (en) 2002-02-12 2004-06-17 Massey Steven Marc Synthetic excitatory amino acids
WO2003068750A1 (en) 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Jnk inhibitor
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
WO2003070712A1 (en) 2002-02-19 2003-08-28 H. Lundbeck A/S Thioibotenic acid and derivatives thereof
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
AU2003223953A1 (en) 2002-03-14 2003-09-22 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003226737B2 (en) 2002-03-29 2008-09-04 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
WO2003084610A1 (en) 2002-04-03 2003-10-16 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
JP4606161B2 (ja) 2002-05-21 2011-01-05 アムジエン・インコーポレーテツド 置換複素環式化合物および使用方法
US7371872B2 (en) 2002-06-11 2008-05-13 Eli Lilly And Company Prodrugs of excitatory amino acids
RU2333208C2 (ru) 2002-06-13 2008-09-10 Вертекс Фармасьютикалз Инкорпорейтед Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
GB0218800D0 (en) 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004018386A2 (en) 2002-08-26 2004-03-04 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
CA2496577A1 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
JP2006501265A (ja) 2002-09-10 2006-01-12 ノバルティス アクチエンゲゼルシャフト 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
WO2004024936A2 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Mutant forms of glutamate receptors mglur2 and mglur3
JP4391426B2 (ja) 2002-09-19 2009-12-24 ベーリンガー インゲルハイム （カナダ） リミテッド 非ヌクレオシド逆転写酵素インヒビター
JP2006505532A (ja) 2002-09-19 2006-02-16 ベーリンガー インゲルハイム （カナダ） リミテッド 非ヌクレオシド逆転写酵素インヒビター
TW200410975A (en) 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US7998163B2 (en) 2002-10-03 2011-08-16 Boston Scientific Scimed, Inc. Expandable retrieval device
JP4327094B2 (ja) 2002-10-23 2009-09-09 積水メディカル株式会社 脱フルクトシル化方法
US20040138204A1 (en) 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
BR0315897A (pt) 2002-11-01 2008-05-13 Abbott Lab agentes antiinfecciosos
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
AU2003289386A1 (en) 2002-12-18 2004-07-09 Takeda Pharmaceutical Company Limited Jnk inhibitors
WO2004060313A2 (en) 2002-12-30 2004-07-22 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
ITMI20030151A1 (it) 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
EP1592684B1 (en) 2003-02-04 2008-07-30 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20070066590A1 (en) 2003-02-24 2007-03-22 Jones Robert M Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
EP1601358B1 (en) 2003-03-03 2007-12-19 F. Hoffmann-La Roche Ag 2,5-substituted tetrahydroisoquinolines for use as 5-ht6 modulators
ITFI20030058A1 (it) 2003-03-06 2004-09-07 Univ Firenze Formulazioni farmaceutiche contenenti tiazolidinedioni
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
WO2005002585A1 (en) 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AU2004257748B2 (en) 2003-07-14 2008-10-30 Decode Genetics Ehf. Method of diagnosis and treatment for asthma based on haplotype association
GB0320300D0 (en) 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
MXPA06009019A (es) 2004-02-18 2007-03-08 Astrazeneca Ab Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico.
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
WO2005089752A2 (en) 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2005233437A1 (en) 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
US8063004B2 (en) 2004-07-22 2011-11-22 Malcera, L.L.C. Chemical composition of matter for the liquefaction and dissolution of asphaltene and paraffin sludges into petroleum crude oils and refined products at ambient temperatures and method of use
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
AU2005269546A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
JP2008508306A (ja) 2004-07-30 2008-03-21 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体のインダノン増強剤
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
JP5276322B2 (ja) 2004-08-11 2013-08-28 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 虚血性心疾患の超音波診断方法及び装置
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
DE102004044884A1 (de) 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101048157A (zh) 2004-10-25 2007-10-03 默克公司 代谢型谷氨酸受体的杂环二氢茚酮增强剂
PT1817300E (pt) 2004-11-22 2010-05-28 Lilly Co Eli Potenciadores de receptores de glutamato
US7434262B2 (en) 2004-12-08 2008-10-07 At&T Intellectual Property I, L.P. Methods and systems that selectively resurrect blocked communications between devices
DE102004061288A1 (de) 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
WO2006071730A1 (en) 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
CA2603959A1 (en) 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
JPWO2006137350A1 (ja) 2005-06-22 2009-01-15 キッセイ薬品工業株式会社 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
DE202005011415U1 (de) 2005-07-13 2005-10-06 Arnold & Richter Cine Technik Gmbh & Co Betriebs Kg Vorrichtung zur elektrischen Kontaktierung von Leuchtmitteln in Scheinwerfern
AU2006279034A1 (en) 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
JP2009509921A (ja) 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
WO2007027669A1 (en) 2005-08-29 2007-03-08 Cps Biofuels, Inc. Improved biodiesel fuel, additives, and lubbricants
EP1764099A3 (en) 2005-09-17 2007-05-09 Speedel Experimenta AG Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV
DE602006007481D1 (de) 2005-09-17 2009-08-06 Novartis Ag 5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6-ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
WO2008051197A2 (en) 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
TW200732313A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
WO2007103760A2 (en) 2006-03-02 2007-09-13 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
WO2007135527A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
AU2007262147B2 (en) 2006-06-19 2012-08-16 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
WO2008006540A1 (en) * 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008012622A2 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008032191A2 (en) 2006-09-13 2008-03-20 Astrazeneca Ab Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
CA2665195C (en) 2006-10-11 2011-08-09 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CN101605792A (zh) 2007-02-09 2009-12-16 阿斯利康(瑞典)有限公司 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CL2008000669A1 (es) 2007-03-07 2008-11-03 Janssen Pharmaceutica Nv Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras.
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
WO2008109737A1 (en) 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EA200970837A1 (ru) 2007-03-07 2010-04-30 Янссен Фармацевтика Н.В. ЗАМЕЩЁННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ α-РЕЦЕПТОРА ЭСТРОГЕНА
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
SG10201506994RA (en) 2007-03-09 2015-10-29 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2008130853A1 (en) 2007-04-17 2008-10-30 Astrazeneca Ab Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
DE602008004794D1 (de) 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
WO2009041567A1 (ja) * 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2244576A4 (en) 2008-01-24 2011-06-08 Merck Sharp & Dohme 3,5-substituted-1,3-oxazolidine-2-one derivatives
EP2268645B1 (en) 2008-03-06 2014-11-12 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
DE102008001056A1 (de) 2008-04-08 2009-10-15 Robert Bosch Gmbh Umlenkeinrichtung für einen Strahl einer elektromagnetischen Welle
JP2011520890A (ja) 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
EP2279532A4 (en) 2008-05-15 2011-07-27 Merck Sharp & Dohme OXAZOLBENZIMIDAZOLDERIVATE
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
AT507619B1 (de) 2008-12-05 2011-11-15 Oesterreichisches Forschungs Und Pruefzentrum Arsenal Ges M B H Verfahren zur approximation des zeitlichen verlaufs von verkehrsdaten
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
WO2010114726A1 (en) 2009-03-31 2010-10-07 Merck Sharp & Dohme Corp. Aminobenzotriazole derivatives
EP2417135A1 (en) 2009-04-07 2012-02-15 Schering Corporation Substituted triazolopyridines and analogs thereof
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010141360A1 (en) 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
WO2011022312A1 (en) 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
CN102002040A (zh) 2009-09-01 2011-04-06 上海药明康德新药开发有限公司 一种三唑并吡啶环化合物的合成方法
AR078172A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
AR078173A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
WO2011034741A1 (en) 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
JP5204071B2 (ja) 2009-09-25 2013-06-05 パナソニック株式会社 電気かみそり
US8507521B2 (en) 2009-11-02 2013-08-13 Merck Sharp + Dohme B.V. Heterocyclic derivatives
EP2542083B1 (en) 2010-03-04 2015-05-06 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
US8748632B2 (en) 2010-03-19 2014-06-10 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group II mGluRs
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
EP2563143A4 (en) 2010-04-29 2013-09-25 Merck Sharp & Dohme SUBSTITUTED 1,3-BENZOTHIAZOL-2 (3H) -ONE AND [1,3-] THIAZOLO- [5,4-B] PYRIDINE-2 (-1H) -ONE AS POSITIVE ALLOSTERE MODULATORS OF MGLUR2
BR112012027628A2 (pt) 2010-04-30 2016-08-09 Astrazeneca Ab polimorfos de um modulador alostérico positivo de receptor de glutamato metabotrópico
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
CN101893589B (zh) 2010-06-29 2012-10-17 中国人民解放军第三0二医院 一种无菌检查方法及其使用的全封闭集菌安瓿培养器
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
US8785481B2 (en) 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
CA2814998C (en) * 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328196A1 (en) 2010-11-08 2013-05-02 Janssen Pharmaceuticals, Inc. Radiolabelled mGluR2 PET ligands
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2012151139A1 (en) 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Alkyne benzotriazole derivatives
US20140088151A1 (en) 2011-05-03 2014-03-27 Douglas C. Beshore Alhydroxymethyl biaryl benzotriazole derivatives
JP6211797B2 (ja) 2012-05-14 2017-10-11 パナソニック株式会社 除臭剤を備えた除臭装置、および除臭装置を備えた冷蔵庫
US9191739B2 (en) 2013-03-25 2015-11-17 Bose Corporation Active reduction of harmonic noise from multiple rotating devices
JP6211798B2 (ja) 2013-05-17 2017-10-11 富士機械製造株式会社 基板上の異物検査方法および異物検査装置

Also Published As

Publication number Publication date
ZA201107834B (en) 2012-12-27
TWI468406B (zh) 2015-01-11
TW201100416A (en) 2011-01-01
KR20120059453A (ko) 2012-06-08
PT2430022E (pt) 2013-12-26
CL2011002838A1 (es) 2012-04-09
HK1169405A1 (en) 2013-01-25
CA2760741A1 (en) 2010-11-18
JP5634506B2 (ja) 2014-12-03
RS53075B (sr) 2014-04-30
CN102439008B (zh) 2015-04-29
CN102439008A (zh) 2012-05-02
BRPI1012870A2 (pt) 2016-04-05
DK2430022T3 (da) 2013-12-02
EA201190303A1 (ru) 2012-06-29
CA2760741C (en) 2018-05-01
US20120184525A1 (en) 2012-07-19
EA020672B1 (ru) 2014-12-30
NZ596078A (en) 2013-06-28
ME01573B (me) 2014-09-20
HRP20131122T1 (hr) 2013-12-20
CY1114718T1 (el) 2016-10-05
SI2430022T1 (sl) 2014-04-30
JP2012526737A (ja) 2012-11-01
IL215912A0 (en) 2012-01-31
BRPI1012870B1 (pt) 2020-10-13
EP2430022B1 (en) 2013-11-20
PL2430022T3 (pl) 2014-02-28
UA108070C2 (uk) 2015-03-25
WO2010130424A1 (en) 2010-11-18
BRPI1012870B8 (pt) 2021-05-25
US9737533B2 (en) 2017-08-22
JO2907B1 (en) 2015-09-15
US20150141403A1 (en) 2015-05-21
SG10201402250TA (en) 2014-07-30
US8937060B2 (en) 2015-01-20
SMT201400003B (it) 2014-03-07
KR101753826B1 (ko) 2017-07-04
ES2440001T3 (es) 2014-01-27
WO2010130424A9 (en) 2011-01-27
EP2430022A1 (en) 2012-03-21
AU2010246609B2 (en) 2013-09-05
IL215912A (en) 2015-02-26
SG176021A1 (en) 2011-12-29
MX2011011964A (es) 2012-02-23
US20160067245A1 (en) 2016-03-10
US20170333426A1 (en) 2017-11-23
MY161325A (en) 2017-04-14
US9226930B2 (en) 2016-01-05
US10071095B2 (en) 2018-09-11
AU2010246609A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
AR076861A1 (es) Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
HRP20171999T1 (hr) Novi derivati aminopirimidina
PE20130346A1 (es) Compuestos heterociclicos fusionados
CO6190512A2 (es) Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso
PE20141557A1 (es) Derivado de pirazoloquinolina
AR080467A1 (es) Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR072042A1 (es) Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
AR072900A1 (es) Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
PE20130779A1 (es) Pirimidinas y triazinas condensadas y su uso
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
AR053699A1 (es) Derivados de tetrahidro-1h-pirido[4,3-b]indoles como ligandos de receptores cb1
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure